Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Captor Therapeutics Operating Margin % Related Terms
Captor Therapeutics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CTX vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Captor Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Captor Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -3,433.54% mean?
Captor Therapeutics (WAR:CTX) has a Operating Margin % of -3,433.54% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Captor Therapeutics and its competitors. According to the industry distribution chart, Captor Therapeutics ranks #788 out of 939 companies in the Biotechnology industry, placing it in the top 83.9%.
Is Captor Therapeutics' Operating Margin % too high?
Captor Therapeutics' current Operating Margin % is -3,433.54%. Based on the distribution chart, Captor Therapeutics ranks #788 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #788 out of 939 companies for Operating Margin %. This places Captor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current Operating Margin % is -3,433.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current Operating Margin % is -3,433.54%. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Operating Margin % is -3,433.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
Operating Margin %: -3,433.54%
GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score
Get the complete analysis for WAR:CTX
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
